Cefpirome sulfate

Cefpirome sulfate (CAS No.: 98753-19-6) is a semisynthetic fourth generation cephalosporin antibacterial research compound within the beta lactam class, widely used as a reference tool in microbiology, antibacterial pharmacology, and anti infective discovery workflows to investigate broad spectrum activity profiles against Gram negative and Gram positive bacteria, including susceptible anaerobic organisms and selected beta lactamase producing strains. Its primary mechanism is high affinity interaction with bacterial penicillin binding proteins, leading to inhibition of peptidoglycan cross linking and disruption of cell wall biosynthesis, which drives bactericidal effects and growth suppression in susceptible organisms, and this mechanism is generally studied in the context of cell envelope biogenesis pathways rather than host signaling networks. Reported in vitro potency for this class is commonly characterized by minimum inhibitory concentrations spanning low micromolar to sub micromolar equivalent exposure ranges depending on species, strain background, inoculum conditions, and resistance determinants, while quantitative readouts in individual studies are typically benchmarked using standardized susceptibility assays and time kill designs. In biomedical research settings, cefpirome sulfate is applied in bacterial culture systems, resistance mechanism characterization, comparator arm design for beta lactam optimization programs, and translational infection model development, including experiments that examine tissue penetration behavior such as blood brain barrier relevant exposure paradigms in preclinical animals, with the concentrations or doses used in experiments typically depending on specific experimental designs and research objectives.